...FDA granted Orphan Drug designation to subcutaneous veltuzumab to treat pemphigus. The humanized anti-CD20 antibody has completed...
...to out-license the compound. Immunomedics Inc. (NASDAQ:IMMU), Morris Plains, N.J. Product: Subcutaneous veltuzumab ( hA20 , IMMU-106...

...Immunomedics said Takeda terminated a 2008 deal and returned to Immunomedics rights to subcutaneous veltuzumab , a...
...proceedings in September to settle its allegations that delays by Takeda's Nycomed unit in developing veltuzumab...
...arbitration for damages. In 2008, Immunomedics granted Nycomed exclusive, worldwide rights to develop and commercialize subcutaneous veltuzumab...

...week after Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) terminated a 2008 deal and returned rights to subcutaneous veltuzumab...
...development of veltuzumab. In May, Nycomed said it was planning a Phase II trial of veltuzumab...

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) terminated a 2008 deal and returned to Immunomedics rights to subcutaneous veltuzumab...
...started arbitration proceedings to settle its allegations that delays by Takeda's Nycomed unit in developing veltuzumab...
...arbitration for damages. In 2008, Immunomedics granted Nycomed exclusive, worldwide rights to develop and commercialize subcutaneous veltuzumab...

...Humanized mAb Phase III for MS Immunomedics Inc. (NASDAQ:IMMU)/Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) Veltuzumab (hA20; IMMU-106...

...portion of an open-label, U.S. Phase I/II trial showed that weekly 200 mg/m 2 IV veltuzumab-RAP...
...partial responses. The trial is enrolling patients with NHL who failed >=1 prior standard regimen. Veltuzumab-RAP...

...portion of an open-label, U.S. Phase I/II trial showed that weekly 200 mg/m 2 IV veltuzumab-RAP...
...Nuclear Medicine and Molecular Imaging meeting in Vancouver. Immunomedics Inc. (NASDAQ:IMMU), Morris Plains, N.J. Product: Veltuzumab-Rap...

...include two Type I antibodies: TG Therapeutics Inc. 's glycoengineered ublituximab and Immunomedics Inc. 's veltuzumab...

...for the period ended March 31 that Takeda's Nycomed company will pursue clinical development of subcutaneous veltuzumab...
...believe that the SLE market has fewer therapeutic options, which offers greater commercial potential for veltuzumab...
...a humanized anti-CD20 antibody. Nycomed has exclusive, worldwide rights from Immunomedics to develop and commercialize subcutaneous veltuzumab...

...Interim data from 42 evaluable patients in a Phase I/II trial showed that subcutaneous veltuzumab produced an...
...defined as platelet levels >=100,000/µL. In patients who have had ITP for <=1 year (n=12), subcutaneous veltuzumab...
...Morris Plains, N.J. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Veltuzumab ( hA20 , IMMU-106...